Catalog No.: PC-24698Not For Human Use, Lab Use Only.
PAT-1102 (FNDR-20123) is a novel, potent, orally available HDAC inhibitor with IC50 of 3 nM in cell-free HDAC enzymatic assays, also inhibits Plasmodium HDAC with IC50 of 31 nM.
PAT-1102 (FNDR-20123) is a novel, potent, orally available HDAC inhibitor with IC50 of 3 nM in cell-free HDAC enzymatic assays, also inhibits Plasmodium HDAC with IC50 of 31 nM. PAT-1102 (FNDR-20123) inhibits P. falciparum in asexual blood-stage assay with IC50 of 42 nM. PAT-1102 (FNDR-20123) shows activities against various HDAC isoforms, HDAC1, 2, 3, 6 and 8. PAT-1102 (FNDR-20123) induces caspase-3 activation in HT-29 cells with EC50 of 1.36 uM. PAT-1102 (FNDR-20123) exhibits growth-inhibitory properties against a panel of cancer cell lines. PAT-1102 (FNDR-20123) (50 mg/kg, p.o.) induces significant dose-dependent tumor growth inhibition in subcutaneous xenograft model established with HCT-116 colorectal carcinoma cells in SCID mice. PAT-1102 (FNDR-20123) exhibits vivo efficacy in a mouse model for Plasmodium falciparum infection.
